Drug Type Small molecule drug |
Synonyms DNX-114 |
Target |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization DNX Biopharmaceuticals, Inc.Startup |
Active Organization DNX Biopharmaceuticals, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
AS | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Arthritis, Psoriatic | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Juvenile Idiopathic Arthritis | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Plaque psoriasis | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |
Rheumatoid Arthritis | Preclinical | US | DNX Biopharmaceuticals, Inc.Startup | 31 Aug 2022 |